Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
02/25/2022* -- Results Q4 2021 -- -0.99 --
02/25/2022* 08:30 EST Earnings Call Q4 2021 -- -- --
11/09/2021 -- Results Q3 2021 -0.95 -0.92 -3.27%
11/09/2021 08:30 EST Earnings Call Q3 2021 -- -- --
08/09/2021 -- Results Q2 2021 -0.85 -0.79 -7.47%
08/09/2021 08:00 EST Earnings Call Q2 2021 -- -- --
05/10/2021 -- Results Q1 2021 -0.65 -0.80 18.37%
05/10/2021 08:30 EST Earnings Call Q1 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 02/25/2022
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/09/2021
Beat/Miss Upgrade
Return Since -2.80%
Last FQE 09/30/2021
Next FQE 12/30/2021

Profile

Edit
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
URL https://www.intracellulartherapies.com
Investor Relations URL https://ir.intracellulartherapies.com/
HQ State/Province New York
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Equity Style Small Cap/Growth
Next Earnings Release Feb. 25, 2022
Last Earnings Release Nov. 09, 2021
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
204.8%
-71.95%
-4.04%
-21.34%
201.2%
-7.32%
64.59%
-17.71%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-2.11%
--
--
--
-47.66%
56.34%
101.7%
-17.43%
-17.55%
--
--
--
--
28.09%
434.1%
143.1%
-19.39%
-45.24%
-25.26%
139.2%
14.66%
16.61%
69.15%
20.97%
-0.31%
30.59%
16.16%
-32.92%
-22.45%
67.88%
95.85%
119.3%
-27.60%
As of January 14, 2022.

Profile

Edit
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
URL https://www.intracellulartherapies.com
Investor Relations URL https://ir.intracellulartherapies.com/
HQ State/Province New York
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Equity Style Small Cap/Growth
Next Earnings Release Feb. 25, 2022
Last Earnings Release Nov. 09, 2021
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
WGMCX 79.88M USD 2.65%
BBP 448746.0 USD 2.49%
XPH 4.171M USD 1.95%
LCMGX 7.010M USD 1.91%
DLRHX 18.22M USD 1.83%
NPSGX 2.126M USD 1.80%
FRBRX 19.74M USD 1.72%
PFC4304 893139.0 USD 1.60%
PINV.TO 893139.0 USD 1.60%
PILL 311208.0 USD 1.33%
IHE 4.374M USD 1.11%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Stocktwits ITCI Tweets